- Net revenue was $982 million in the first quarter, which is down 4% as reported, and 6% in constant currency from Q1 2023
- Overall organic net revenue decreased by 8% year-over-year during the three-month period
- The company reported a net loss of $715 million for the September quarter, including non-cash goodwill impairment charges of $700 million
- On a per-share basis, Q1 loss was $3.94, vs. breakeven in the year-ago quarter
- Q1 adjusted net loss was $19 million or $0.10 per share, compared to adjusted profit of $61 million or $0.34 per share last year
- Adjusted EBITDA came in at $115 million, down 38% as reported, and 39% in constant currency, compared to last year
- For fiscal 2024, the company expects net revenue to be in the range of $4.30 billion to $4.50 billion
Market News
Earnings Summary: Highlights of Catalent’s Q1 2024 results
Catalent, Inc. (NYSE: CTLT), a provider of delivery technologies and development solutions to the pharmaceutical industry, has reported earnings for the first quarter of 2024. Net revenue was $982 million in the first quarter, which is down 4% as reported, and 6% in constant currency from Q1 2023 Overall organic net revenue decreased by 8% […]
“Catalent, Inc. (NYSE: CTLT), a provider of delivery technologies and development solutions to the pharmaceutical industry, has reported earnings for the first quarter of 2024. Net revenue was $982 million in the first quarter, which is down 4% as reported, and 6% in constant currency from Q1 2023 Overall organic net revenue decreased by 8% […]
· November 15, 2023
Catalent, Inc. (NYSE: CTLT), a provider of delivery technologies and development solutions to the pharmaceutical industry, has reported earnings for the first quarter of 2024.
ADVERTISEMENT